PR87857

AMERSHAM, United Kingdom, Feb. 1, 2021 /PRNewswire=KYODO JBN/--

- Cytiva will now provide "idea to injection" solutions to customers and the

  market

- Addition to portfolio supports global trends towards smaller manufacturing

  and the advent of personalized therapies

- First acquisition by company since becoming Cytiva in April 2020

Cytiva has acquired Vanrx Pharmasystems (

https://c212.net/c/link/?t=0&l=en&o=3052489-1&h=3767644611&u=https%3A%2F%2Fvanrx.com%2F&a=Vanrx+Pharmasystems

), a Canadian company that makes robotic aseptic filling machines to fill

vials, syringes, and cartridges with reduced risk and increased speed to

patients.  

Photo - https://mma.prnewswire.com/media/1429615/SA25_Front_Operator.jpg

Logo - https://mma.prnewswire.com/media/1138636/cytiva_Logo.jpg

This is the first acquisition by Cytiva. Emmanuel Ligner, President and CEO,

Cytiva, says: "Since becoming a Danaher operating company in April 2020, we

have already begun fueling innovation and re-investing in the business for the

benefit of our customers and their patients.  We are thrilled to welcome the

Vanrx associates to our family and look forward to working together on

delivering meaningful solutions for biomanufacturers."

The Vanrx portfolio complements Cytiva's manufacturing capacity solutions.

Whereas great progress has until now focused on drug substances, this

innovation is focused on drug product, which is a critical last step before

distribution to patients.  Global trends toward smaller batches and

personalized therapies are changing the growing USD 300 billion biologics

market[1], and the complete bioprocessing workflow must include aseptic filling

solutions.

Olivier Loeillot, Vice President and Head of BioProcess, Cytiva, says: "Cytiva

becomes the first 'idea to injection' biotechnology company by bringing Vanrx

into our already strong portfolio. From drug development, through drug

substance and now into drug product, we can help biomanufacturers bring their

therapies to patients faster. Vanrx will enhance Cytiva FlexFactory platforms

and KUBio modular facilities, enabling us to accelerate biomanufacturing from

start to finish."

Vanrx's flagship products are the SA25 Aseptic Filling Workcell (

https://c212.net/c/link/?t=0&l=en&o=3052489-1&h=4066222055&u=https%3A%2F%2Fvanrx.com%2Fproducts%2Fsa25-aseptic-filling-workcell%2F&a=SA25+Aseptic+Filling+Workcell

) and Microcell Vial Filler (

https://c212.net/c/link/?t=0&l=en&o=3052489-1&h=2272059585&u=https%3A%2F%2Fvanrx.com%2Fproducts%2Fmicrocell-vial-filler%2F&a=Microcell+Vial+Filler

), which automate aseptic filling using robotics within closed, gloveless

isolators. These standardized, flexible systems provide a fast and certain path

to filling capacity as the final step in manufacturing clinical and commercial

biopharmaceuticals. The company counts leading biopharmaceutical companies as

its customers.

Vanrx was founded in 2007 by Chris Procyshyn and Ross Gold and currently has

over 120 associates, all of whom have been offered employment with Cytiva.

Chris Procyshyn, Vanrx co-founder and CEO, says: "We created Vanrx to enable

every company to manufacture safe and cost-effective injectable therapies. Our

own experience told us that new technologies are needed to support

next-generation therapies and personalized medicine.

"Cytiva is a perfect home for what we have built. Thanks to their reach, we

will be able to help our current and future customers change the lives of even

more patients around the world."

Producers: Click here for B-roll (

https://c212.net/c/link/?t=0&l=en&o=3052489-1&h=4072886993&u=https%3A%2F%2Fwww.cytivalifesciences.com%2Fen%2Fus%2Fabout-us%2Fmedia%2Fmedia-gallery&a=Click+here+for+B-roll+

) of aseptic filling solutions.

Click here for more information (

https://c212.net/c/link/?t=0&l=en&o=3052489-1&h=3189705594&u=https%3A%2F%2Fwww.cytivalifesciences.com%2Fen%2Fus%2Fsolutions%2Fenterprise-solutions&a=Click+here+for+more+information

) about Cytiva's enterprise solutions.

About Cytiva

Cytiva is a global life sciences leader with more than 7,000 associates across

40 countries dedicated to advancing and accelerating therapeutics. As a trusted

partner to customers that range in scale and scope, Cytiva brings speed,

efficiency and capacity to research and manufacturing workflows, enabling the

development, manufacture and delivery of transformative medicines to patients.

(1) BioPlan and Associates 17th Annual Biopharmaceutical Manufacturing Capacity

and Production (April 2020)

SOURCE: Cytiva

Media Contacts: Europe:

                Dodi Axelson

                Dodi.axelson@cytiva.com; or

                USA, Canada:

                Colleen Connolly

                Colleen.connolly@cytiva.com